Children with optic pathway gliomas (OPGs) frequently experience vision loss from their tumors. Standard front-line treatment using carboplatin-based chemotherapy typically produces only a modest benefit (eg, stabilization or 0.2 logMAR improvement) in visual acuity (VA). Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor and acts primarily as an anti-angiogenic agent. Recent reports suggest a qualitative improvement in vision after bevacizumab-based treatment in children with OPGs.
We report 4 cases of pediatric OPGs (2 neurofibromatosis type 1–related and 2 sporadic cases) that received treatment with bevacizumab due to progressive VA or visual field (VF) loss despite prior treatment with chemotherapy or proton-beam radiation. All 4 subjects demonstrated a marked improvement in their VA, VF, or both while receiving bevacizumab-based therapy. Three patients had complete resolution of their VA or VF loss in at least 1 eye—2 of whom had previously received bevacizumab therapy.
Conclusions and Relevance
Given that most patients with OPG-related visual impairment will show modest or no visual improvement with standard treatment, the incorporation of bevacizumab in these cases may greatly improve visual outcomes and should be considered in appropriate clinical situations.
Chiasmatic optic pathway glioma in an 11-year-old girl (case 1) with neurofibromatosis type 1 with dense temporal visual field loss (left panel). Improvement was seen in the visual field and tumor size/enhancement within 7 months of treatment with bevacizumab/irinotecan (middle panel). The visual field continued to improve and remained stable 6 months after treatment was discontinued (right panel).
Sporadic (non–neurofibromatosis type 1–related) optic pathway glioma in a 13-year-old girl (case 2) with previously normal visual acuity (20/20, OD/OS) that presented with a decline in visual acuity and a left hemifield defect respecting the vertical meridian 7 months after proton-beam therapy (left panel). Improvement in vision and tumor size/enhancement occurred within 2 months of starting bevacizumab treatment (middle panel) and remained stable at 12 months (right panel).
Sporadic chiasmatic/hypothalamic optic pathway glioma in a 6-year-old girl (case 4), with a decline in visual acuity 4 months after proton-beam therapy (left panel). Within 5 months of starting bevacizumab, her visual acuity improved, along with a noticeable decrease in tumor size and enhancement (middle panel). Bevacizumab was discontinued because of a positive treatment response. Vision remained stable despite an increase in size and enhancement (right panel) 9 months after discontinuation of bevacizumab. CF indicates counting fingers.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.